Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Patients with chronic lymphocytic leukemia (CLL) have a suboptimal humoral response to vaccination. Recently, BNT162b2, an mRNA COVID-19 vaccine with a high efficacy of 95% in immunocompetent individuals, was introduced. We investigated the safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine...

Descrición completa

Detalles Bibliográficos

Principais autores:	Ohad Benjamini, Lior Rokach, Gilad Itchaki, Andrei Braester, Lev Shvidel, Neta Goldschmidt, Shirley Shapira, Najib Dally, Abraham Avigdor, Galia Rahav, Yaniv Lustig, Shirley Shapiro Ben David, Riva Fineman, Alona Paz, Osnat Bairey, Aaron Polliack, Ilana Levy, Tamar Tadmor
Formato:	Artigo
Idioma:	Inglês
Publicado:	Ferrata Storti Foundation 2021-07-01
Series:	Haematologica
Acceso en liña:	https://haematologica.org/article/view/10351
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!